Tumor genomic profiling helps identify actionable mutations to guide targeted therapies and clinical decisions. Understanding when to use it is key to maximizing its impact in precision oncology.
Cancer has long been recognized as a biologically heterogeneous disease, yet historically it has often been treated using relatively uniform therapeutic approaches.
As a cornerstone of precision oncology, MRD monitoring is shaping the future of cancer care through more accurate, data-driven decision-making.

A multidisciplinary community committed to advancing research, education, and clinical standards in precision medicine.
Copyright 2026. American Board of Precision Medicine. All Rights Reserved.